Key Points
-
Polymer therapeutics are nano-sized medicines. The definition encompasses polymeric drugs (polymeric molecules that are biologically active in their own right); polymer–drug conjugates; polymer–protein conjugates; polymeric micelles to which drug is covalently bound; and polymeric non-viral vectors for gene delivery.
-
An increasing number of biologically active polymers and polymeric sequestrants are entering routine clinical use as macromolecular drugs. Multivalent synthetic polymers are also being developed as improved vaccines and anti-toxin therapeutics.
-
Covalent conjugation of synthetic polymers — particularly polyethyleneglycol (PEG) — to protein drugs increases their plasma residence, reduces protein immunogenicity and can increase therapeutic index. Several PEGylated enzymes (adenosine deaminase, L-asparaginase) and cytokines (including interferon α and G-CSF) have now entered routine clinical use.
-
Polymer conjugation dramatically alters the biodistribution of a low molecular weight drug, affording the opportunity to achieve disease-specific targeting with reduced access to sites of toxicity. Eleven polymer antitumour conjugates have been transferred into clinical development. They have been designed for lysosomotropic delivery following passive tumour targeting by the enhanced permeability and retention (EPR) effect, or, in one case, for receptor-mediated targeting by introduction of a cell-specific ligand.
-
Cationic or bio-responsive polymers that change conformation on exposure to the lower intracellular pH of endosomes and lysosomes are being developed as an alternative to viral vectors, for intracytoplasmic delivery of genes and proteins.
-
Those polymers that have been exploited clinically have a linear polymer architecture. The principles for the design of polymer therapeutics are now being applied to novel hyperbranched polymers, dendrimers and dendritic polymer architectures.
-
Before clinical evaluation, it is essential to establish the safety of novel polymers, particularly with respect to general toxicity, immunogenicity and metabolic fate.
Abstract
As we enter the twenty-first century, research at the interface of polymer chemistry and the biomedical sciences has given rise to the first nano-sized (5–100 nm) polymer-based pharmaceuticals, the 'polymer therapeutics'. Polymer therapeutics include rationally designed macromolecular drugs, polymer–drug and polymer–protein conjugates, polymeric micelles containing covalently bound drug, and polyplexes for DNA delivery. The successful clinical application of polymer–protein conjugates, and promising clinical results arising from trials with polymer–anticancer-drug conjugates, bode well for the future design and development of the ever more sophisticated bio-nanotechnologies that are needed to realize the full potential of the post-genomic age.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Duncan, R., Dimitrijevic, S. & Evagorou, E. G. The role of polymer conjugates in the diagnosis and treatment of cancer. S. T. P. Pharma Sciences 6, 237–263 (1996).
Donaruma, L. G. Synthetic biologically active polymers. Progr. Polym. Sci. 4, 1–25 (1974).
Duncan, R. in Handbook of Anticancer Drug Development (eds Budman, D., Calvert, H. & Rowinsky, E.) (Lippincott Williams & Wilkins, Baltimore, in the press). A detailed overview describing the rationale for the design and current clinical status of polymer–anticancer-drug conjugates.
Harris, J. M. & Chess, R. B. Effect of pegylation on pharmaceuticals. Nature Rev. Drug Discov. 2, 214–221 (2003). An excellent review describing PEG–protein technology and the current clinical status of PEGylated protein pharmaceuticals. An important complementary review to the one presented here.
Veronese, F. M. & Harris, J. M. (eds). Special issue: Peptide and protein PEGylation. Adv. Drug Deliv. Systems 54, 453–609 (2002).
Yokoyama, M. et al. Polymeric micelles as novel drug carrier: Adriamycin-conjugated poly(ethylene glycol)–poly(aspartic acid) block copolymer. J. Control Release 11, 269–278 (1990).
Kabanov, A. V., Felgner, P. L. & Seymour, L. W. Self–assembling Complexes for Gene Delivery. From Laboratory to Clinical Trial (Wiley, Chichester, 1998).
Fuertges, F. & Abuchowski, A. The clinical efficacy of poly(ethylene glycol)-modified proteins. J. Cont. Rel. 11, 139–148 (1990).
Jatzkewitz, H. Peptamin (glycyl-L-leucyl-mescaline) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine (mescaline). Z. Naturforsch. 10, 27–31 (1955).
Regelson, W. & Parker, G. The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy. Cancer Invest. 4, 29–42 (1986).
Ringsdorf, H. Structure and properties of pharmacologically active polymers. J. Polymer Sci. Polymer Symp. 51, 135–153 (1975).
Gros, L., Ringsdorf, H. & Schupp, H. Polymeric antitumour agents on a molecular and on a cellular level? Angew. Chem. Int. Edn Engl. 20, 305–325 (1981). The starting point for the development of the modern concepts of polymer–drug conjugates and polymeric micelles.
Davis, F. F. The origin of pegnology. Adv. Drug Deliv. Rev. 54, 457–458 (2002).
Ferber, D. Gene therapy: Safer and virus-free? Science 294, 1638–1640 (2001).
Niidome, T. & Huang, L. Gene therapy progress and prospects: Nonviral vectors. Gene Ther. 9, 1647–1652 (2002).
Gore, M. E. Gene therapy can cause leukaemia: no shock, mild horror but a probe. Gene Ther. 10, 4 (2003). Observations indicating that retroviral gene insertion is linked with leukaemia in two children previously treated with gene therapy for severe combined immunodeficiency syndrome have refuelled interest in the design of effective nonviral vectors for gene therapy.
Brocchini, S. & Duncan, R. in Encyclopaedia of Controlled Drug Delivery (ed. Mathiowitz, E.) 786–816 (Wiley, New York, 1999). A comprehensive review describing the many polymers that have been used to synthesize polymer–drug conjugates.
Rihova, B. Antibody-targeted polymer-bound drugs. Folia Microbiol. 40, 367–384 (1995).
Nori, A. et al. Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconj. Chem. 14, 44–50 (2003).
Satchi, R., Connors, T. A. & Duncan, R. PDEPT: Polymer directed enzyme prodrug therapy. I. HPMA copolymer–cathepsin B and PK1 as a model combination. Brit. J. Cancer 85, 1070–1076 (2001).
Mammen, M., Choi, S. -K. & Whitesides, G. M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn Engl. 37, 2754–2794 (1998).
Stiriba, S. E., Krautz, H. & Frey, H. Hyperbranched molecular nanocapsules: Comparisons of the hyperbranched architecture with the perfect linear analogue. J. Am. Chem. Soc. 124, 9698–9699 (2002).
Ferruti, P. et al. A novel modification of poly(L-lysine) leading to a soluble cationic polymer with reduced toxicity and with potential as a transfection agent. Macromol. Chem. Phys. 199, 2565–2575 (1998).
Dautzenberg, H. et al. Polycationic graft copolymers as carriers for oligonucleotide delivery. Complexes of oligonucleotides with polycationic graft copolymers. Langmuir 17, 3096–3102 (2001).
Tomalia, D. A. et al. A new class of polymers — starburst-dendritic macromolecules. Polym. J. 17, 117–132 (1985). The start of the dendrimer chemistry revolution.
Frechet, J. M. J. Dendrimers and hyperbranched polymers: two families of three-dimensional macromolecules with similar but clearly distinct properties. J. Mater. Sci. Pure Appl. Chem. 33, 1399–1425 (1996).
Frechet, J. M. J. & Tomalia, D. A. Dendrimers and Other Dendritic Polymers (Wiley, Chichester, 2001).
Malenfant, P. R. L. & Frechet, J. M. J. in Dendrimers and Other Dendritic Polymers (eds Frechet, J. M. J. & Tomalia, D. A.) 171–196 (Wiley, Chichester, 2001).
Pechar, M., Ulbrich, K. & Subr, V. Poly(ethyleneglycol) multiblock copolymer as a carrier of anticancer drug doxorubicin. Bioconj. Chem. 11, 131–139 (2000).
Mirhra, M. K. & Kobayashi, S. Star and Hyperbranched Polymers (Marcel Dekker, Basel, 1999).
Roy, R. Recent developments in the rational design of multivalent glycoconjugates. Top. Curr. Chem. 187, 241–274 (1997).
Chaves, F. et al. Synthesis, isolation and characterization of Plasmodium falciparum antigenic tetrabranched peptide dendrimers obtained by thiazolidine linkages. J. Pept. Res. 58, 307–316 (2001).
Martin, C. R. & Kohli, P. The emerging field of nanotube biotechnology. Nature Rev. Drug Discov. 2, 29–37 (2003).
Painter, P. C. & Coleman, M. C. Fundamentals of Polymer Science 2nd edn (CRC, Boca Raton, 1997).
Cavagnaro, J. A. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nature Rev. Drug Discov. 1, 469–476 (2002).
Seymour, L. W. Synthetic polymers with intrinsic anticancer activity. J. Bioact. Comp. Polymers 6, 178–216 (1991).
Breslow, D. S. Biologically active synthetic polymers. Pure Appl. Chem. 46, 103–113 (1976).
Regelson, W. Advances in intraperitoneal (intracavitary) administration of synthetic polymers for immunotherapy and chemotherapy. J. Bioact. Comp. Polymers 1, 84–106 (1986).
Mistry, C. D. & Gokal, R. Icodextrin in peritoneal dialysis: Early development and clinical use. Perit. Dial. Int. 14 (Suppl. 2), 13–21 (1994).
Jarvan, C. M. et al. Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages. AIDS Res. Hum. Retroviruses 13, 875–880 (1997).
Shaunak, S. et al. Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin-2-sulphate in patients with AIDS. AIDS 12, 399–409 (1998). Dextrin-2–sulphate was the first sulphated polysaccharide to be administered clinically via the peritoneal route.
Thornton, M. et al. Anti-Kaposi's sarcoma and angiogenic activities of sulfated dextrins. Antimicrob. Agents Chemother. 43, 2528–2533 (1999).
Stafford, M. K. et al. A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: novel potential intravaginal virucide. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14, 213–218 (1997).
Teitlebaum, M. S. D., Arnon, R. & Sela, M. Copaxone in experimental allergic encephalomyelitis and animal model for CMLS. Cell Biol. Life Sci. 53, 24–28 (1997).
Johnson, K. P. et al. Copaxone disease progression. Neurology 45, 1268–1276 (1995).
Slatopolsky, E. A. et al. RenaGel®, a nonabsorbed calcium- and phosphate-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int. 55, 299–307 (1999).
Mandeville, W. H. & Goldberg, D. I. The sequestration of bile acids, a non-absorbed method for cholersterol reduction. A review. Curr. Pharm. Des. 3, 15–28 (1997).
Gregoriadis, G. et al. Polysialic acids: potential in drug delivery. FEBS Lett. 315, 271–276 (1993).
Roy, R. et al. Synthesis and antigenic properties of sialic acid-base dendrimers. ACS Symp. Ser. 560, 104–119 (1994).
Sigal, G. B. et al. Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: The strong inhibition reflects enhanced binding through cooperative polyvalent interactions. J. Am. Chem. Soc. 118, 3789–3800 (1996).
Rihova, B. & Riha, I. Immunological problems of polymer-bound drugs. Crit. Rev. Ther. Drug Carrier Syst. 1, 311–374 (1985).
Rihova, B. Biocompatibility of biomaterials: Haemocompatibility, immunocompatibility and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers. Adv. Drug Deliv. Rev. 21, 157–176 (1996). An excellent review addressing the issues relating to the safety of polymeric materials and water soluble polymers used as drug carriers.
Seymour, L. W. et al. Effect of molecular weight (Mω) of N-(2-hydroxypropyl) methacrylamide copolymers on body distributions and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J. Biomed. Mat. Res. 21, 1341–1358 (1987).
Kobayashi, H. et al. Micro-MR angiography of normal and intratumoural vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer-based MR contrast agents. J. Magn. Reson. Imaging 14, 705–713 (2001).
Robinson, B. V. et al. PVP: A Critical Review of the Kinetics and Toxicology of Polyvinylpyrrolidone (Povidone). (Lewis, Chelsea, 1990).
Seymour, L. W. et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 31, 766–770 (1995).
Volfova, I. et al. Biocompatibility of biopolymers. J. Bioact. Biocompat. Polymers 7, 175–190 (1992).
Rihova, B. Immunogenicity of N-(2-hydroxypropyl) methacrylamide copolymers. Makromol. Chem. 9, 13–24.
Rihova, B. et al. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect of haematopoietic stem cells in bone marrow in vivo and effect on mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 10, 335–342 (1989).
Yeung, T. K. et al. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl) methacrylamide conjugates: an experimental study in the rat. Cancer Chemother. Pharmacol. 29, 105–111 (1991).
Duncan, R., Coatsworth, J. K. & Burtles, S. Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer–doxorubicin (PK1). Hum. Exp. Toxicol. 17, 93–104 (1998). The first paper describing a good laboratory practice (GLP) preclinical toxicological study of a polymer–drug conjugate.
Nagle, T. et al. The further evolution of biotech. Nature Rev. Drug Discov. 2, 75–79 (2003).
Brekke, O. H. & Sandlie, I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nature Rev. Drug Discov. 2, 52–62 (2003).
Nucci, M. L., Shorr, D. & Abuchowski, A. The therapeutic values of poly(ethylene glycol)-modified proteins. Adv. Drug Deliv. Rev. 6, 133–151 (1991).
Delgado, C., Francis, G. E. & Fisher, D. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. 9, 249–304 (1992).
Monfardini, C. & Veronese, F. M. Stabilisation of substances in the circulation. Bioconj. Chem. 9, 418–450 (1998).
Francis, G. et al. Polyethylene glycol modification: Relevance to improved methodology to tumour targeting. J. Drug Target. 3, 321–340 (1996).
Roberts, M. J., Bentley, M. D. & Harris, J. M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54, 459–476 (2002).
Goodson, R. J. & Katre, N. V. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology 8, 343–346 (1990).
Chapman, A. P. et al. Therapeutic antibody fragments with prolonged in vivo half-lives. Nature Biotechnol. 17, 780–783 (1999).
Sato, H. Enzymatic procedure for site-specific pegylation of proteins. Adv. Drug Deliv. Rev. 54, 487–504 (2002).
Bailon, P. & Berthold, W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today 1, 352–356 (1998).
Lee, S et al. Drug delivery systems employing 1,6-elimination: Releasable poly(ethylene glycol) conjugates of proteins. Bioconj. Chem. 12, 163–169 (2001).
Levy, Y. et al. Adenosine deaminase deficiency with late onset or recurrent infections: response to treatment with polyethylene glycol modified adenosine deaminase. J. Pediatr. 113, 312–317 (1988).
Graham, M. L. PEGASPARAGINASE: a review of clinical studies. Adv. Drug Deliv. Rev. (in the press).
Kinstler, O. et al. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 54, 477–485 (2002).
Reddy, K. R., Modi, M. W. & Pedder, S. Use of peginterferon α-2a (40KD) (Pegasys®) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 54, 571–586 (2002).
Wang, Y. -S. et al. Structural and biological characterisation of pegylated recombinant interferon α-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54, 547–570 (2002).
Bukowski, R. et al. Pegylated interferon α-2b treatment for patients with solid tumors: a phase I/II study. J. Clin. Oncol. 20, 3841–3849 (2002).
De Duve, C. et al. Lysosomotropic agents. Biochem. Pharmacol. 23, 2495–2531 (1974).
Huang, P. S. & Oliff, A. Drug-targeting strategies in cancer therapy. Curr. Opin. Genet. Dev. 11, 104–110 (2001).
Duncan, R. & Spreafico, F. Polymer conjugates: Pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 27, 290–306 (1994).
Matsumura, Y. & Maeda, H. A new concept for macromolecular therapies in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res. 6, 6387–6392 (1986).
Seymour, L. W. et al. Tumouritropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Brit. J. Cancer 70, 636–641 (1994).
Gianasi, E. et al. HPMA copolymer platinates as novel antitumor agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur. J. Cancer 35, 994–1002 (1999).
Rejmanova, P. et al. Stability in plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers. Biomaterials 6, 45–48 (1985).
Duncan, R. et al. Polymers containing enzymatically degradable bonds. 7. Design of oligopeptide side chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem. 184, 1997–2008 (1984).
Etrych, T. et al. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Control Release 73, 89–102 (2001).
Kopecek, J. & Bazilova, H. Poly[N-(hydroxypropyl) methacrylamide]. I. Radical polymerisation and copolymerisation. Eur. Polymer J. 9, 7–14 (1973).
Sprincl, L. et al. New types of synthetic infusion solutions. III. Elimination and retention of poly[N-(2-hydroxypropyl) methacrylamide] in a test organism. J. Biomed. Mater. Res. 10, 953–963 (1976).
Duncan, R. & Kopecek, J. Soluble synthetic polymers as potential drug carriers. Adv. Polymer Sci. 57, 51–101 (1984).
Duncan, R. Drug–polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 3, 175–210 (1992).
Duncan, R. et al. Preclinical evaluation of polymer-bound doxorubicin. J. Control Release 19, 331–346 (1992). An important paper describing the preclinical and in vivo antitumour studies that paved the way for HPMA copolymer–doxorubicin to enter clinical testing.
Kopecek, J. et al. HPMA copolymer–anticancer drug conjugates: design, activity and mechanism of action. Eur. J. Pharm. Biopharm. 50, 61–81 (2000).
Vasey, P. et al. Phase I clinical and pharmacokinetic study of PKI (N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin): first member of a new class of chemotherapeutic agents — drug–polymer conjugates. Clin. Cancer Res. 5, 83–94 (1999). The first Phase I clinical trial evaluating a synthetic polymer–drug conjugate as an anticancer agent.
Seymour, L. W. et al. Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20, 1668–1676 (2002). The first clinical study describing a synthetic biomimetic polymer conjugate. HPMA copolymer–doxorubicin containing additional galactose residues was designed to target the hepatocyte asialoglycoprotein receptor.
Thomson, A. H. et al. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Brit. J. Cancer 81, 99–107 (1999).
Duncan, R. et al. Fate of N-(2-hydroxypropyl) methacrylamide copolymers with pendant galactosamine residues after intravenous administration to rats. Biochim. Biophys. Acta 880, 62–71 (1986).
Ashwell, G. & Harford, J. Carbohydrate recognition systems of the liver. Ann. Rev. Biochem. 51, 531–554 (1982).
Julyan, P. J. et al. Preliminary clinical study of the distribution of HPMA copolymer–doxorubicin bearing galactosamine. J. Control Release 57, 281–290 (1999).
Meerum Terwogt, J. M. et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12, 315–323 (2001).
Schoemaker, N. E. et al. A phase I and pharmacokinetic study of MAG-CPT, a water soluble polymer conjugate of camptothecin. Brit. J. Cancer 87, 608–614 (2002).
Li, C. et al. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)–paclitaxel conjugate. Cancer Res. 58, 2404–2409 (1998). An important study describing preclinical properties of PGA–paclitaxel.
Sludden, A. V. et al. Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)–paclitaxel conjugate. Proc. Am. Assoc. Cancer Res. 42, 2883 (2001).
Sabbatini, P. et al. A phase I/II study of PG–paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer. Proc. Am. Soc. Clin. Oncol. 871 (2002).
Kudelka, A. P. et al. Preliminary report of a phase I study of escalating dose PG–paclitaxel (CT-2103) and fixed dose cisplatin in patients with solid tumors Proc. Am. Soc. Clin. Oncol. 2146 (2002).
Schulz, J. et al. Phase II study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with a 5-fluorouracil-containing regimen. Proc. Am. Soc. Clin. Oncol. 2330 (2002).
Shaffer, S. A. et al. Metabolism of poly-L-glutamic acid (PG)–paclitaxel (CT-2103); proteolysis by lysosomal cathepsin B and identification of intermediate metabolites. Proc. Am. Assoc. Cancer Res. 43, 2067 (2002).
Denis, L. et al. A Phase I study of PEG–camptothecin (PEG–CPT) in patients with advanced solid tumours: A novel formulation for an insoluble but active agent. Proc. Am. Soc. Clin. Oncol. 19, 700 (2000).
Greenwald, R. B. et al. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55, 217–250 (2003).
Rice, J. R., Stewart, D. R. & Nowotnik, D. P. Enhanced antitumour activity of a new polymer linked DACH–platinum complex. Proc. Am. Assoc. Cancer Res. 43, 307 (2002).
Gianasi, E. et al. HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. J. Drug Targeting 10, 549–556 (2002).
Ochi, Y. et al. DE-310, a novel macromolecular carrier for the camptothecin analogue DX-8951f[II]: Its antitumour activities in several model systems of human and murine tumours. Proc. Am. Assoc. Cancer Res. 42, 748 (2001).
De Vries, P. et al. Optimisation of CT2106: a water soluble poly-L-glutamic acid (PG)–camptothecin conjugate with enhanced in vivo antitumor efficacy. Proc. AACR-NCI-EORTC Int. Conf. 100 (2001).
Batrakova, E. V. et al. Anthracycline antibiotics non-covalently incorporated into block copolymer micelles: in vivo evaluation of anticancer activity. Br. J. Cancer 74, 1545–1552 (1996).
Alakhov, V. et al. Block copolymer-based formulations of doxorubicin. From cell screen to clinical trials. Colloids Surf. B: Biointerfaces 16, 113–134 (1999). The first micelle-based formulation of doxorubicin, and its transfer to the clinic.
Kataoka, K. et al. Block copolymer micelles as vehicles for drug delivery. J. Control Release 24, 119–132 (1993).
Nakanishi, T. et al. Development of the polymer micelle carrier system for doxorubicin. J. Control Release 74, 295–302 (2001). A description of the preclinical development of the first micelle-based doxorubicin formulation containing covalently bound drug.
Sat, Y. N. et al. Comparison of vascular permeability and enzymatic activation of the polymeric prodrug HPMA copolymer–doxorubicin (PK1) in human tumour xenografts. Proc. Am. Assoc. Cancer Res. 90, 41 (1999).
Jain, R. K. Delivery of molecular and cellular medicine to solid tumours. Adv. Drug Deliv. Rev. 46, 149–168 (2001).
Wu, J., Akaike, T. & Maeda, H. Modulation of enhanced vascular permeability in tumours by a bradykinin antagonist, a cyclooxygenase inhibitor. Cancer Res. 58, 159–165 (1998).
Li, C. et al. Tumour irradiation enhances the tumour-specific distribution of poly(L-glutamic acid)–conjugated paclitaxel and its antitumour efficacy. Clin. Cancer Res. 6, 2829–2834 (2000).
Boussif, O. et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl Acad. Sci. USA 92, 7297–7301 (1995).
Remy, J. -S. et al. Gene transfer with lipospermines and polyethylenimines. Adv. Drug Deliv. Rev. 30, 85–95 (1998).
Merdan, T. et al. Intracellular processing of poly(ethyleneimine)/ribozyme complexes can be observed in living cells by using confocal laser scanning microscopy and inhibitor experiments. Pharm. Res. 19, 140–146 (2002).
Brunner, S. et al. Overcoming the nuclear barrier: cell cycle independent nonviral gene transfer with linear polyethylenimine or electroporation. Mol. Ther. 5, 80–86 (2002).
Wightman, L. et al. Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. J. Gene Med. 3, 362–372 (2001).
Kircheis, R. et al. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther. 8, 28–40 (2001).
Lisziewicz, J. et al. Induction of potent human immunodeficiency virus type 1-specific T cell-restricted immunity by genetically modified dendritic cells. J. Virol. 75, 7621–7628 (2001).
Vernejoul, F. Antitumor effect of in vivo somatostatin receptor sst2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res. 62, 6124–6131 (2002).
Ferruti, P., Marchisio, M. A. & Duncan, R. Poly(amido-amine)s: Biomedical applications Macromol. Rapid Comm. 23, 332–355 (2002).
Stayton, P. S. et al. Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics. J. Control Release 65, 203–220 (2000).
Putnam, D. et al. Polymer-based gene delivery with low cytotoxicity by a unique balance of side chain termini. Proc. Natl Acad Sci. USA 98, 1200–1205 (2001).
Satchi-Fainaro, R. et al. PDEPT: Polymer directed enzyme prodrug therapy. II. HPMA copolymer-β-lactamase and HPMA-C-Dox as a model combination. Bioconj. Chem. (in the press).
Duncan, R. et al. Polymer–drug conjugates, PDEPT and PELT: Basic principles for design and transfer from the laboratory to the clinic. J. Control Release 74, 135–146 (2001).
Gopin, A. et al. A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger. Angew. Chem. Int. Edn Engl. 42, 327–332 (2003).
Kerbel, R. & Folkman, J. Clinical translation of angiogenic inhibitors. Nature Rev. Cancer 2, 727–739 (2002).
Satchi-Fainaro, R. et al. Polymer therapeutics of angiogenesis inhibitors: HPMA copolymer–TNP-470 conjugate. Proc. Intl Symp. Controlled Rel. Bioact. Mater. 29, 209–210 (2002). An excellent paper describing in vitro and in vivo activity of the first polymer anti-angiogenic conjugate.
Tomlinson, R. et al. Pendent chain functionalised polyacetals that display pH-dependent degradation: A platform for the development of novel polymer therapeutics. Macromolecules 35, 473–480 (2002).
Gillies, E. R. & Frechet, J. M. J. Designing macromolecules for therapeutic applications: Polyester dendrimer–poly(ethylene oxide) 'bow-tie' hybrids with tunable molecular weight and architecture. J. Am. Chem. Soc. 124, 14137–14146 (2002).
Cloninger, M. J. Biological applications of dendrimers. Curr. Opin. Chem. Biol. 6, 742–748 (2002).
Wiwattanapatapee, R. et al. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: A potential oral delivery system. Pharm. Res. 17, 991–998 (2000).
Lendlein, A. & Langer, R. Biodegradable, elastic, shape-memory polymers for potential biomedical applications. Science 296, 1673–1676 (2002).
Chanda, S. K. & Caldwell, J. S. Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov. Today 8, 168–174 (2003).
Atkins, J. H. & Gershell, L. J. Selective anticancer drugs. Nature Rev. Cancer 1, 645–646 (2002).
The Journal of Gene Medicine, www.wiley.co.uk.genmed (2002).
Jain, R. K. The next frontier of molecular medicine: Delivery of therapeutics. Nature Med. 4, 655–657 (1998).
Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nature Rev. Drug Discov. 2, 750–763 (2002). An excellent review describing ligands and technologies that have been explored for tumour targeting. Includes information on antibodies, immunoliposomes, immunotoxins and immuno–polymer conjugates.
Langer, R. Drug delivery and targeting. Nature 392, 5–10 (1998).
Iwai, K., Maeda, H. & Konno, T. Use of oily contrast medium for selective drug targeting to tumour: Enhanced therapeutic effect and X-ray image. Cancer Res. 44, 2114–2121 (1984).
Konno, T. & Maeda, H. in Neoplsma of the Liver (eds Okada, K. & Ishak, K. G.) 343–352 (Springer, New York, 1987).
Maeda, H. & Konno, T. in Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug (eds Maeda, H., Edo, K. & Ishida, N.) 227–267 (Springer, Berlin, 1997).
Jain, R. K. Delivery of molecular and cellular medicines to solid tumours. Adv. Drug Deliv. Rev. 26, 71–90 (1997).
Mukherjee, A. et al. How to optimise pegvisomant treatment of acromegaly safely? Endocrine Abstracts 4, OC8 (2002).
Author information
Authors and Affiliations
Related links
Related links
DATABASES
Cancer.gov
MEDLINEplus
FURTHER INFORMATION
Glossary
- MICELLES
-
A self-assembling colloidal aggregate of amphipathic molecules — in this case, polymeric block copolymers — to give a polymeric micelle, which occurs when the concentration reaches the crucial micelle concentration.
- POLYPLEX
-
A polyelectrolyte complex. The term is usually used to describe the complex formed by a polycation and an anionic oligonucleotide or plasmid. The term interpolyelectrolyte complex (IPEC) is also used.
- BIOACTIVE
-
A substance capable of eliciting a measurable biological response.
- BIOMIMETIC
-
A term that describes a structure that is designed to mimic the properties of a natural macromolecule, for example, a synthetic multivalent ligand designed for receptor interaction.
- DENDRIMER
-
A macromolecule containing symmetrically arranged branches arising from a multifunctional core. Repeated reaction sequences add a precise number of terminal groups at each step or generation.
- SUPRAMOLECULAR SYSTEM
-
Self-assembled objects generated by intermolecular noncovalent interactions. They may be super molecules or polymolecular assemblies.
- APOPTOSIS
-
A mechanism of programmed cell death, which occurs when a cell receives mixed internal signals for growth or when stimulated by an external trigger. Apoptosis can be initiated when a cell is no longer needed, or when a cell becomes a threat to the organism's health.
- ANGIOGENESIS
-
The process by which small new blood vessels are formed by budding from existing vessels in both normal and diseased (for example, tumour) tissue.
- HAEMOLYTIC
-
Materials that cause breakage of the red blood cell membrane, and the release of haemoglobin.
- ENDOCYTOSIS
-
Internalization of the cell's plasma membrane to form vesicles that capture macromolecules and particles present in the extracellular fluid and/or bound to membrane-associated receptors. These vesicles then undergo a complex series of fusion events directing the internalized substances to an appropriate intracellular compartment.
- LYSOSOMOTROPIC
-
A term that describes molecules that are delivered to lysosomes and accumulate there. In this context, it is applied to polymeric constructs that are taken into the cell by endocytosis.
- GAMMA CAMERA
-
A device incorporating very sensitive radiation detectors, which produces images of the distribution of radioactivity in the body in patients who have been injected with small amounts of radioactive materials. These images can be used to detect and locate disease (such as cancer) if it is present. The device itself does not emit radiation.
- ENDOSOMOTROPIC
-
A term that describes molecules that are delivered to the endosomal compartment of the cell and accumulate there. In this context, it is applied to polymer constructs that are designed as viral mimetics with the aim of breaching the endosomal membrane, and delivering proteins and oligonucleotides into the cytoplasm of the cell.
Rights and permissions
About this article
Cite this article
Duncan, R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2, 347–360 (2003). https://doi.org/10.1038/nrd1088
Issue Date:
DOI: https://doi.org/10.1038/nrd1088
This article is cited by
-
Recent advancement of nanostructured materials: a compatible therapy of tissue engineering and drug delivery system
Polymer Bulletin (2024)
-
A review on microfluidic-assisted nanoparticle synthesis, and their applications using multiscale simulation methods
Discover Nano (2023)
-
Image-guided cancer surgery: a narrative review on imaging modalities and emerging nanotechnology strategies
Journal of Nanobiotechnology (2023)
-
A niche-mimicking polymer hydrogel-based approach to identify molecular targets for tackling human pancreatic cancer stem cells
Inflammation and Regeneration (2023)
-
Fundamental concepts of protein therapeutics and spacing in oncology: an updated comprehensive review
Medical Oncology (2023)